期刊文献+

p33^(ING1)蛋白在食管鳞状细胞癌中异位表达的临床病理意义 被引量:1

Study on the clinicopathological significance of abnormal expression of p33^(ING1) protein in esophageal squamous cell carcinoma
下载PDF
导出
摘要 目的探讨p33ING1蛋白在食管鳞状细胞癌中异常表达的临床病理意义。方法采用免疫组化的方法检测20例正常食管黏膜组织和64例食管鳞状细胞癌组织中p33ING1蛋白的表达并分析其临床病理意义。结果p33ING1蛋白在食管鳞状细胞癌中的阳性表达部位主要在细胞核和细胞质中,其阳性表达率为35.94%(23/64),而在正常食管黏膜组织中主要表达在细胞核中,阳性表达率为95.00(19/20),二者比较差异有统计学意义(P<0.05)。食管鳞状细胞癌中淋巴结转移阳性表达率为15.00%,淋巴结无转移阳性表达率为45.45%,二者比较差异有统计学意义(P<0.05)。p33ING1蛋白的表达与患者性别、年龄及肿瘤大小、位置和组织学分级均无相关性(P>0.05)。结论p33ING1蛋白在食管鳞状细胞癌的发生发展中可能有重要的作用,其表达部位由细胞核转移到细胞质可能是其抑瘤功能丧失而促使肿瘤发生的主要机制之一。 Objective To investigate the clinicalpathological significance of abnormal expression of p33ING1 protein in esophageal squamous cell carcinoma. Methods The S-p immunohistochemical method was used to detect the expression of p33ING1 from 20 cases of normal esophageal mucous tissue and 64 cases of esophageal squamous cell carcinoma (ESCC),and to investigate the significance of expression of p33^ING1 protein. Results The site of positive expression of p33^ING1 protein in esophageal squamous cell carcinoma was mainly in nuclear and cytoplasm,and the positive rate was 35.94%(23/64),but the positive expression site in normal esophageal mucosa was only in nuclear,and the positive rate was 95% (19/20),there was a significant difference between the two different tissues(P〈0.05). The positive rate of p33ING1 protein expression was 15.00% in lymph node metastasis group and 45.45% in non-lymph node metastasis group,there was a significant difference between the two groups (P〈0.05). The p33ING1 protein expression was not correlated with patient's gender,age and tumor size,location and histological classification (P〉0.05). Conclusion The p33^ING1 protein may play an important role in the genesis and development of esophageal squamous cell carcinoma,one of the most important mechanisms of tumor genesis may be the translation of the p33ING1 protein from nuclear to cytoplasm.
出处 《河北医药》 CAS 2009年第22期3038-3040,共3页 Hebei Medical Journal
基金 河北省科学技术研究与发展指导计划资助项目(编号:062761285)
关键词 p33ING1蛋白 食管鳞状细胞癌 免疫组织化学 临床病理 异常表达 p33ING1 protein esophageal squamous cell carcinoma immunohistochemistry clinicalpathological significance abnormal expression
  • 相关文献

参考文献5

二级参考文献38

  • 1于观贞,朱明华,祝峙,倪灿荣,陈颖,李芳梅.胰腺癌中p33^(ING1b)基因变化及其表达研究[J].肿瘤,2005,25(1):33-36. 被引量:10
  • 2郭艳萍,李珊珊,闫爱华,卢创新,王新华.食管癌中△Np63与p33蛋白表达的意义[J].肿瘤基础与临床,2006,19(2):93-95. 被引量:2
  • 3Garkavtsev I, Kazarov A, Gudkov A, et al. Suppression of the novel growth inhibitor P33/ING1 promotes neoplastic transformation. Nat-Genet, 1996, 14 (2) :415
  • 4Helbing C,Veillette CC, Riabowol K, et al. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res, 1997, 57(7) :1 255
  • 5Tokunage E, Maehara Y, Oki E, et al. Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Lett, 2000, 152( 1 ) :15
  • 6Oki E, Maehara Y, Tokunage E, et al. Reduced expression of p33 (ING1) and the relationship with p53 expression in human gastric cancer. Cancer Lett, 1999, 147 ( 1-2 ): 157
  • 7Chen L, Matsubera, Yoshino T, et al. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. cancer research, 2001, 61: 4345
  • 8Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma, Gut, 2000,46 ( 5 ) :645
  • 9Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumouigenesis. Cancer,2001,91 ( 11 ) :2 026
  • 10Mills AA,Zheng B,Wang XJ,et al. p63 is a p53 homologue required for limb and epidermal morphogenesis [J]. Nature, 1999, 398(6729):708 -713.

共引文献22

同被引文献8

  • 1丁娅,张晓实,彭瑞清,张蓉,张念华,李志铭,刘继彦,马锦,程霞,苏义顺,曾益新.重组人p53腺病毒注射液治疗晚期实体肿瘤的安全性和近期疗效评价[J].中国临床药理学与治疗学,2005,10(9):1025-1029. 被引量:10
  • 2Van Hagen P, Hulshof M, Van Lanschot J J B, et al. Preop- erative chemoradiotherapy for esophageal or junctional cancer [ J]. New England Journal of Medicine, 2012, 366 (22) : 2074.
  • 3Koshy M, Esiashvilli N, Landry J C, et al. Multiple manage- ment modalities in esophageal cancer: epidemiology, presen- tation and progression, work-up, and surgical approaches [J]. The Oncologist, 2004, 9(2) : 137.
  • 4Westerterp M, Koppert L B, Buskens C J, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction [ J ]. Virchows Archiv, 2005, 446(5) : 497.
  • 5Nerlov C. The C/EBP family of transcription factors: a para- digm for interaction between gene expression and proliferation control[J]. Trends in cell biology, 2007, 17(7) : 318.
  • 6Shimada H, Matsubara H, Shiratori T, et al. Phase I/II ade- noviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma [ J ]. Cancer Science, 2006. 97 (6) : 554.
  • 7康艳霞,张贺龙.肿瘤热疗机制的研究进展[J].现代肿瘤医学,2008,16(3):473-475. 被引量:77
  • 8赫捷,邵康.中国食管癌流行病学现状、诊疗现状及未来对策[J].中国癌症杂志,2011,21(7):501-504. 被引量:454

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部